comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 23:39:01 - browse：17

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

hotspot

WSS

Influencer to be charged after chaos erupts in New York City's Union Square

What Mike Pence has said that could be used in a Donald Trump trial

Biden calls for immediate release of Niger's president amid apparent coup

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

White House drug shortage group privately met with industry

The creative science of coining drug names

hotspot

comprehensive

knowledge

Affirmative action in medical school literally saved lives

A cyberattack has disrupted hospitals and health care in several states

Medical leaders decry Supreme Court decision on affirmative action

The creative science of coining drug names

Drug repurposing or repositioning? The language matters

Most antidepressants don't work on kids, teens, study finds

The cancer drug shortage isn’t new — and neither are the solutions

Brain technologies pose threats that are all too real, experts warn

Drug repurposing or repositioning? The language matters

ProMED, early warning system on disease outbreaks, in peril

knowledge

What Henrietta Lacks settlement says about racism in medicine

Attacks on the drug industry will lead to fewer breakthroughs

The drug industry sees a key ally in the Senate prevail

Gilgo Beach: Police identify another victim in serial killing investigation

For BCIs, commercial hurdles may be bigger than scientific ones

Nearly two

knowledge

hotspot

hotspot

leisure time